Polypharmacy

The NIH has awarded a $3.3 million grant to advance a novel, oral silent allosteric modulator intended to treat Alzheimer’s and Parkinson’s diseases, according to the manufacturer.

A polypill containing multiple blood pressure-lowering drugs may be an effective solution to addressing both uncontrolled hypertension and polypharmacy causing non-adherence to antihypertensive medications, speakers reported.

Medication adherence, the extent to which an individual’s behavior corresponds to a health care provider’s recommendations, remains an unaddressed challenge in health care.

Patients who are on dialysis consider polypharmacy as “a necessary evil,” even when they do not notice positive effects, according to results of a study published in Kidney Medicine.

Men with CAD taking nitrates for chest pain plus a PDE5 inhibitor for erectile dysfunction were at greater risk for death or major adverse CV events compared with men taking nitrates alone, Swedish registry data show.

Medical cannabis use for chronic pain may confer increased risk for de novo arrhythmia compared with nonuse or other treatments for chronic pain, researchers in Denmark reported.

More than one in five children on Medicaid are exposed to at least one major drug interaction annually, according to findings from a study published in Pediatrics.

Patients with atopic dermatitis with comorbidities face additional treatment burdens and barriers, according to a study published in Annals of Allergy, Asthma & Immunology.

Patients with post-incident dementia were more likely to begin central nervous system medications and less likely to discontinue cardiometabolic and anticholinergic medications, reflecting missed deprescribing opportunities, according to researchers.

Renal denervation lowered blood pressure out to 36 months, regardless of baseline antihypertensive class combinations and polypharmacy burden, according to an analysis of the Global SYMPLICITY Registry DEFINE.